PennLive reports regulators bumped the risk class on a GLP-1 recall involving an ingredient linked to Mounjaro and Zepbound. Details are at the link.
Recap by typeshit. Post by PennLive.com on X.
Some people on weight loss drugs are testing lower doses, hoping for fewer side effects. ThePrint reports on the trend, which these users describe themselves.
Bell raises the question of muscle loss for people losing weight on a GLP-1 and notes it isn't medical advice, pointing viewers to their doctor.
Dr. Woo points to the official position of the AAO and NANOS on whether routine eye exams just to check for NAION are needed.
USA TODAY covers the copycat GLP-1 crackdown, from the Apothecary Pharma recall to an import alert on a Chengdu factory. Novo says it has filed over 130 lawsuits.
His family says his BMI fell from 36 to 22.8 over two years on Wegovy, and he has since joined a cheer team. His doctor says the drug isn't right for every child.
The analysis points to CagriSema filings, a DKK 15b buyback and Wegovy pill capacity, while flagging margin pressure and flat 2026 guidance as risks.
Loading…